Title |
Looking forward to new targeted treatments for chronic spontaneous urticaria
|
---|---|
Published in |
Clinical and Translational Allergy, January 2017
|
DOI | 10.1186/s13601-016-0139-2 |
Pubmed ID | |
Authors |
Emek Kocatürk, Marcus Maurer, Martin Metz, Clive Grattan |
Abstract |
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU. Off-licence uses of currently available drugs include rituximab and tumour necrosis factor inhibitors. Ligelizumab (anti-IgE), canakinumab (anti-IL-1), AZD1981 (a PGD2 receptor antagonist) and GSK 2646264 (a selective Syk inhibitor) are currently in clinical trials for CSU. Examples of drugs that could target potential pathophysiological targets in CSU include substance P antagonists, designed ankyrin repeat proteins, C5a/C5a receptor inhibitors, anti-IL-4, anti-IL-5 and anti-IL-13 and drugs that target inhibitory mast cell receptors. Other mediators and receptors of likely pathogenic relevance should be explored in skin profiling and functional proof of concept studies. The exploration of novel therapeutic targets for their role and relevance in CSU should help to achieve a better understanding of its etiopathogenesis. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Romania | 5 | 14% |
United Kingdom | 4 | 11% |
United States | 3 | 8% |
Spain | 3 | 8% |
Canada | 2 | 5% |
Taiwan | 1 | 3% |
Argentina | 1 | 3% |
Austria | 1 | 3% |
Dominican Republic | 1 | 3% |
Other | 2 | 5% |
Unknown | 14 | 38% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 28 | 76% |
Scientists | 4 | 11% |
Practitioners (doctors, other healthcare professionals) | 4 | 11% |
Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 71 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 15% |
Other | 9 | 13% |
Student > Ph. D. Student | 8 | 11% |
Student > Postgraduate | 7 | 10% |
Student > Master | 6 | 8% |
Other | 10 | 14% |
Unknown | 20 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 38% |
Biochemistry, Genetics and Molecular Biology | 5 | 7% |
Immunology and Microbiology | 5 | 7% |
Agricultural and Biological Sciences | 4 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 6 | 8% |
Unknown | 22 | 31% |